👉VTGN is TODAY’S #1 ALERT 👈

Hey there, Folks,

I’ve been on fire 🔥 with my “tactical trade” ideas lately.

A lithium stock I alerted on Thursday surged as high as 16% by Friday morning, and an aerospace engineering stock I also alerted on Thursday ripped more than 54% by Friday afternoon.

And get this… the stock I alerted on Monday last week has rallied an incredible 160% since then!

It is safe to say that the small-cap momentum market is on FIRE once again!

Today, I have another special idea that I think you need to look into right away.

Go to your favorite platform and pull up VistaGen Therapeutics, Inc. (NASDAQ: VTGN) right away.

The first thing you should look at is the strong breakout move it is making right now above the previous resistance level…

You need to pay attention when you find that kind of strength.

When you consider the fact that VTGN has traded over 90% higher from its current level over the last year, you know there is a considerable amount of opportunity.

Make sure you have VTGN front and center on your screen all day!

👉  VTGN is TODAY’S #1 ALERT 👈

Now, let’s dive into the fascinating world of VistaGen Therapeutics, Inc. (NASDAQ: VTGN). This company is making waves in the biotech sector with its innovative approaches to treating mental health disorders. Here are the top five standout aspects that make VistaGen unique among its peers:

1. Revolutionizing Anxiety Treatment with Fasedienol Nasal Spray 🚀

VistaGen’s lead product, fasedienol (PH94B), is a groundbreaking nasal spray designed for the acute treatment of social anxiety disorder (SAD). Unlike traditional oral medications that can take weeks to show effects, fasedienol offers rapid relief within minutes. This non-systemic approach targets the nasal chemosensory neurons, providing a novel mechanism of action that sets it apart from existing therapies. The company has initiated Phase 3 trials to further evaluate its efficacy and safety.

2. Pioneering Pherine-Based Therapies 🧠

VistaGen is at the forefront of developing “pherine” compounds—synthetic neuroactive steroids that modulate brain function through the olfactory system. This innovative approach aims to treat various central nervous system (CNS) disorders, including anxiety and depression, with minimal systemic exposure, potentially reducing side effects. Their pipeline includes multiple pherine candidates targeting different CNS conditions.

3. Expanding Pipeline with Itruvone for Depression 🌈

Beyond anxiety, VistaGen is developing itruvone (PH10), another intranasal pherine compound, for major depressive disorder (MDD). Itruvone has shown promise in early-phase studies, offering rapid antidepressant effects without the typical side effects associated with conventional antidepressants. This positions VistaGen to potentially address a significant unmet need in depression treatment.

4. Positive Momentum and Analyst Recognition 📈

VistaGen has garnered attention from analysts and investors alike. The company received a Zacks Rank #2 (Buy) rating, reflecting positive earnings estimate revisions and a favorable outlook. Such recognition underscores the market’s confidence in VistaGen’s innovative pipeline and strategic direction.

5. Strategic Collaborations Enhancing Global Reach 🌍

VistaGen has formed strategic partnerships to advance its clinical programs and expand its global footprint. Notably, the company collaborated with AffaMed Therapeutics to initiate the PALISADE Global Phase 3 trial for fasedienol, aiming to commercialize the treatment in China and other markets outside the U.S. This collaboration exemplifies VistaGen’s commitment to bringing its novel therapies to a broader patient population.

In summary, VistaGen Therapeutics stands out in the biotech landscape with its innovative pherine-based therapies, rapid-acting intranasal treatments, and strategic collaborations aimed at addressing significant unmet needs in mental health. Their unique approach and expanding pipeline make them a company to watch in the evolving field of CNS therapeutics.

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Virtus Media Group for advertising Vistagen Therapeutics, Inc for a one day marketing program on May 20, 2025. It might seem obvious, but while our client claims not to own any shares in Vistagen Therapeutics, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Vistagen Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.